Scientists discover new antibodies - a promising target for clinical exploration.

Transcript

The currently licenced malaria vaccines and monoclonal antibodies all target a well-known region of the same malaria protein. That protein – the circumsporozoite protein, commonly known as CSP – covers the surface of the parasite as it enters the human skin through a mosquito bite. By targeting CSP, the vaccines aim to stop each malaria parasite in its tracks. But what about other proteins on the sporozoite - the parasite form injected into the blood by the mosquito - or other regions of the CSP protein? In a recent study, scientists screened plasma from malaria-infected individuals for immune responses against sporozoites. Many had developed antibodies against these well-known regions of CSP, but some had developed antibodies targeting a different region of the sporozoite surface. Out of ten new antibodies isolated from these individuals, several were functional – inhibiting the development of later parasite stages that occur in the liver and preventing sporozoite infection in a mouse model of malaria. However, they were targeting a different region of CSP that was only uncovered after processing by the sporozoite. This new region – called pGlu-CSP – is, the authors say, a site of vulnerability and a promising target for future clinical exploration.

Source

Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein (Science)

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.